An Open-Label, Non-Comparative Study to Assess the Pharmacokinetics, Safety and Efficacy of Topical Retapamulin (SB-275833) Ointment, 1 percent, Twice Daily for Five Days in the Treatment of Uncomplicated Skin and Skin Structure Infections in Pediatric Subjects Aged 2 to 24 Months.

Trial Profile

An Open-Label, Non-Comparative Study to Assess the Pharmacokinetics, Safety and Efficacy of Topical Retapamulin (SB-275833) Ointment, 1 percent, Twice Daily for Five Days in the Treatment of Uncomplicated Skin and Skin Structure Infections in Pediatric Subjects Aged 2 to 24 Months.

Completed
Phase of Trial: Phase IV

Latest Information Update: 30 Dec 2016

At a glance

  • Drugs Retapamulin (Primary)
  • Indications Bacterial infections; Skin infections
  • Focus Pharmacokinetics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 05 May 2010 Actual number of patients (87) added as reported by ClinicalTrials.gov record.
    • 27 Oct 2008 Actual end date (Aug 2008) added as reported by ClinicalTrials.gov.
    • 27 Oct 2008 Actual start date changed from Jun 2007 to Sep 2007 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top